Report Detail

Request for Sample of this report

Pharma & Healthcare Global Cancer Immunotherapy Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

  • RnM4743028
    • |
  • 28 September, 2026
    • |
  • Global
    • |
  • 124 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Cancer Immunotherapy Drug market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Cancer Immunotherapy Drugs are medications used in the treatment of cancer. These drugs harness the body"s immune system to target and destroy cancer cells. Immunotherapy drugs are designed to boost the body"s natural defenses against cancer and are used in various forms, including immune checkpoint inhibitors and CAR-T cell therapies.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Cancer Immunotherapy Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Cancer Immunotherapy Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Cancer Immunotherapy Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Cancer Immunotherapy Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Cancer Immunotherapy Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Cancer Immunotherapy Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Cancer Immunotherapy Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Autolus Therapeutics plc, BeiGene, bluebird bio, Inc., Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Gilead Sciences, Inc., Incyte Corporation, Jiangsu Hengrui Medicine, Juno Pharmaceuticals Pty Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Cancer Immunotherapy Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
PD-1 Inhibitor
PDL-1 Inhibitor
T-Cell Stimulant
CTLA Antibody
Market segment by Application
Hospital
Clinic
Others
Major players covered
Autolus Therapeutics plc
BeiGene
bluebird bio, Inc.
Bristol-Myers Squibb
Celgene Corporation
AstraZeneca plc
Gilead Sciences, Inc.
Incyte Corporation
Jiangsu Hengrui Medicine
Juno Pharmaceuticals Pty Ltd.
Medimmune, LLC
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Roche Holding AG
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Cancer Immunotherapy Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Cancer Immunotherapy Drug, with price, sales quantity, revenue, and global market share of Cancer Immunotherapy Drug from 2021 to 2026.
Chapter 3, the Cancer Immunotherapy Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cancer Immunotherapy Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Cancer Immunotherapy Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Cancer Immunotherapy Drug.
Chapter 14 and 15, to describe Cancer Immunotherapy Drug sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Cancer Immunotherapy Drug Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 PD-1 Inhibitor
    • 1.3.3 PDL-1 Inhibitor
    • 1.3.4 T-Cell Stimulant
    • 1.3.5 CTLA Antibody
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Cancer Immunotherapy Drug Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Clinic
    • 1.4.4 Others
  • 1.5 Global Cancer Immunotherapy Drug Market Size & Forecast
    • 1.5.1 Global Cancer Immunotherapy Drug Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Cancer Immunotherapy Drug Sales Quantity (2021-2032)
    • 1.5.3 Global Cancer Immunotherapy Drug Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Autolus Therapeutics plc
    • 2.1.1 Autolus Therapeutics plc Details
    • 2.1.2 Autolus Therapeutics plc Major Business
    • 2.1.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Product and Services
    • 2.1.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Autolus Therapeutics plc Recent Developments/Updates
  • 2.2 BeiGene
    • 2.2.1 BeiGene Details
    • 2.2.2 BeiGene Major Business
    • 2.2.3 BeiGene Cancer Immunotherapy Drug Product and Services
    • 2.2.4 BeiGene Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 BeiGene Recent Developments/Updates
  • 2.3 bluebird bio, Inc.
    • 2.3.1 bluebird bio, Inc. Details
    • 2.3.2 bluebird bio, Inc. Major Business
    • 2.3.3 bluebird bio, Inc. Cancer Immunotherapy Drug Product and Services
    • 2.3.4 bluebird bio, Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 bluebird bio, Inc. Recent Developments/Updates
  • 2.4 Bristol-Myers Squibb
    • 2.4.1 Bristol-Myers Squibb Details
    • 2.4.2 Bristol-Myers Squibb Major Business
    • 2.4.3 Bristol-Myers Squibb Cancer Immunotherapy Drug Product and Services
    • 2.4.4 Bristol-Myers Squibb Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Bristol-Myers Squibb Recent Developments/Updates
  • 2.5 Celgene Corporation
    • 2.5.1 Celgene Corporation Details
    • 2.5.2 Celgene Corporation Major Business
    • 2.5.3 Celgene Corporation Cancer Immunotherapy Drug Product and Services
    • 2.5.4 Celgene Corporation Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Celgene Corporation Recent Developments/Updates
  • 2.6 AstraZeneca plc
    • 2.6.1 AstraZeneca plc Details
    • 2.6.2 AstraZeneca plc Major Business
    • 2.6.3 AstraZeneca plc Cancer Immunotherapy Drug Product and Services
    • 2.6.4 AstraZeneca plc Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 AstraZeneca plc Recent Developments/Updates
  • 2.7 Gilead Sciences, Inc.
    • 2.7.1 Gilead Sciences, Inc. Details
    • 2.7.2 Gilead Sciences, Inc. Major Business
    • 2.7.3 Gilead Sciences, Inc. Cancer Immunotherapy Drug Product and Services
    • 2.7.4 Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Gilead Sciences, Inc. Recent Developments/Updates
  • 2.8 Incyte Corporation
    • 2.8.1 Incyte Corporation Details
    • 2.8.2 Incyte Corporation Major Business
    • 2.8.3 Incyte Corporation Cancer Immunotherapy Drug Product and Services
    • 2.8.4 Incyte Corporation Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Incyte Corporation Recent Developments/Updates
  • 2.9 Jiangsu Hengrui Medicine
    • 2.9.1 Jiangsu Hengrui Medicine Details
    • 2.9.2 Jiangsu Hengrui Medicine Major Business
    • 2.9.3 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product and Services
    • 2.9.4 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Jiangsu Hengrui Medicine Recent Developments/Updates
  • 2.10 Juno Pharmaceuticals Pty Ltd.
    • 2.10.1 Juno Pharmaceuticals Pty Ltd. Details
    • 2.10.2 Juno Pharmaceuticals Pty Ltd. Major Business
    • 2.10.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product and Services
    • 2.10.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
  • 2.11 Medimmune, LLC
    • 2.11.1 Medimmune, LLC Details
    • 2.11.2 Medimmune, LLC Major Business
    • 2.11.3 Medimmune, LLC Cancer Immunotherapy Drug Product and Services
    • 2.11.4 Medimmune, LLC Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Medimmune, LLC Recent Developments/Updates
  • 2.12 Merck & Co., Inc.
    • 2.12.1 Merck & Co., Inc. Details
    • 2.12.2 Merck & Co., Inc. Major Business
    • 2.12.3 Merck & Co., Inc. Cancer Immunotherapy Drug Product and Services
    • 2.12.4 Merck & Co., Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Merck & Co., Inc. Recent Developments/Updates
  • 2.13 Novartis AG
    • 2.13.1 Novartis AG Details
    • 2.13.2 Novartis AG Major Business
    • 2.13.3 Novartis AG Cancer Immunotherapy Drug Product and Services
    • 2.13.4 Novartis AG Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Novartis AG Recent Developments/Updates
  • 2.14 Pfizer, Inc.
    • 2.14.1 Pfizer, Inc. Details
    • 2.14.2 Pfizer, Inc. Major Business
    • 2.14.3 Pfizer, Inc. Cancer Immunotherapy Drug Product and Services
    • 2.14.4 Pfizer, Inc. Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Pfizer, Inc. Recent Developments/Updates
  • 2.15 Roche Holding AG
    • 2.15.1 Roche Holding AG Details
    • 2.15.2 Roche Holding AG Major Business
    • 2.15.3 Roche Holding AG Cancer Immunotherapy Drug Product and Services
    • 2.15.4 Roche Holding AG Cancer Immunotherapy Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Roche Holding AG Recent Developments/Updates

3 Competitive Environment: Cancer Immunotherapy Drug by Manufacturer

  • 3.1 Global Cancer Immunotherapy Drug Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Cancer Immunotherapy Drug Revenue by Manufacturer (2021-2026)
  • 3.3 Global Cancer Immunotherapy Drug Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Cancer Immunotherapy Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Cancer Immunotherapy Drug Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Cancer Immunotherapy Drug Manufacturer Market Share in 2025
  • 3.5 Cancer Immunotherapy Drug Market: Overall Company Footprint Analysis
    • 3.5.1 Cancer Immunotherapy Drug Market: Region Footprint
    • 3.5.2 Cancer Immunotherapy Drug Market: Company Product Type Footprint
    • 3.5.3 Cancer Immunotherapy Drug Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Cancer Immunotherapy Drug Market Size by Region
    • 4.1.1 Global Cancer Immunotherapy Drug Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Cancer Immunotherapy Drug Consumption Value by Region (2021-2032)
    • 4.1.3 Global Cancer Immunotherapy Drug Average Price by Region (2021-2032)
  • 4.2 North America Cancer Immunotherapy Drug Consumption Value (2021-2032)
  • 4.3 Europe Cancer Immunotherapy Drug Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Cancer Immunotherapy Drug Consumption Value (2021-2032)
  • 4.5 South America Cancer Immunotherapy Drug Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Cancer Immunotherapy Drug Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Cancer Immunotherapy Drug Sales Quantity by Type (2021-2032)
  • 5.2 Global Cancer Immunotherapy Drug Consumption Value by Type (2021-2032)
  • 5.3 Global Cancer Immunotherapy Drug Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Cancer Immunotherapy Drug Sales Quantity by Application (2021-2032)
  • 6.2 Global Cancer Immunotherapy Drug Consumption Value by Application (2021-2032)
  • 6.3 Global Cancer Immunotherapy Drug Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Cancer Immunotherapy Drug Sales Quantity by Type (2021-2032)
  • 7.2 North America Cancer Immunotherapy Drug Sales Quantity by Application (2021-2032)
  • 7.3 North America Cancer Immunotherapy Drug Market Size by Country
    • 7.3.1 North America Cancer Immunotherapy Drug Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Cancer Immunotherapy Drug Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Cancer Immunotherapy Drug Sales Quantity by Type (2021-2032)
  • 8.2 Europe Cancer Immunotherapy Drug Sales Quantity by Application (2021-2032)
  • 8.3 Europe Cancer Immunotherapy Drug Market Size by Country
    • 8.3.1 Europe Cancer Immunotherapy Drug Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Cancer Immunotherapy Drug Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Cancer Immunotherapy Drug Market Size by Region
    • 9.3.1 Asia-Pacific Cancer Immunotherapy Drug Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Cancer Immunotherapy Drug Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Cancer Immunotherapy Drug Sales Quantity by Type (2021-2032)
  • 10.2 South America Cancer Immunotherapy Drug Sales Quantity by Application (2021-2032)
  • 10.3 South America Cancer Immunotherapy Drug Market Size by Country
    • 10.3.1 South America Cancer Immunotherapy Drug Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Cancer Immunotherapy Drug Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Cancer Immunotherapy Drug Market Size by Country
    • 11.3.1 Middle East & Africa Cancer Immunotherapy Drug Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Cancer Immunotherapy Drug Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Cancer Immunotherapy Drug Market Drivers
  • 12.2 Cancer Immunotherapy Drug Market Restraints
  • 12.3 Cancer Immunotherapy Drug Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Cancer Immunotherapy Drug and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Cancer Immunotherapy Drug
  • 13.3 Cancer Immunotherapy Drug Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Cancer Immunotherapy Drug Typical Distributors
  • 14.3 Cancer Immunotherapy Drug Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Cancer Immunotherapy Drug. Industry analysis & Market Report on Cancer Immunotherapy Drug is a syndicated market report, published as Global Cancer Immunotherapy Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Cancer Immunotherapy Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo